This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Arno Therapeutics Reports Findings Of New Diagnostic Technique The Potential To Identify Patients With Cancer Who May Respond To Treatment With Onapristone

Arno Therapeutics, Inc. (OTCBB: ARNI), a clinical-stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that researchers have identified a new immunohistochemistry technique for identifying activated progesterone receptors in breast cancer tumors that may be predictive of response to treatment with onapristone, an investigational progestin receptor antagonist being developed by Arno that has demonstrated anti-tumor activity in preclinical and clinical studies. The findings were reported in a poster entitled “Characterization of progesterone receptor biomarker for predicting antiprogestin in human cancers,” presented today at the 35th Annual San Antonio Breast Cancer Symposium.

The poster describes a new technique for identifying the activated form of the progesterone receptor via nuclear morphology that can be done on a routine basis with freshly obtained or paraffin-fixed and paraffin-embedded tissue. The technique is being further refined and tested on a larger cohort of breast and endometrial cancer samples, with correlation to other standard tumor markers and clinical outcomes; these data sets will be presented at a future medical meeting. Additional testing in other malignancies is ongoing. The investigators believe this technique for identifying activated progesterone receptors may allow a method for selecting patients who are most likely to respond to antiprogestins such as onapristone.

Last month at the 24 th European Organization for Research and Treatment of Cancer Symposium on Molecular Targets and Cancer Therapeutics, Arno reported results of preclinical investigations in which cancer cells that express the activated form of the progesterone receptor responded to treatment with onapristone, while cells that did not express the activated form of the progesterone receptor did not respond to onapristone treatment.

Glenn Mattes, president and chief executive officer of Arno Therapeutics, stated, “The continued progress of our research colleagues in describing the predictive value of activated progesterone receptors suggests that we are moving closer to identifying a clinical biomarker that may determine which patients with breast, endometrial and other cancers respond best to treatment with onapristone. This work is very helpful to our efforts to develop a companion diagnostic for onapristone, which is an integral part of our clinical development of onapristone as a potential new cancer therapy.”

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs